Rogers Mailien, Rasheed Atif, Moradimehr Abdolali, Baumrucker Steven J
Department of Internal Medicine, ETSU College of Medicine, Johnson City, Tennessee, USA.
Am J Hosp Palliat Care. 2009 Feb-Mar;26(1):57-9. doi: 10.1177/1049909108330025.
Neuropathic pain is common in the palliative care population; unless adequately treated, the pain can lead to chronic anxiety, depression, and social impairment. Many treatments have been proposed for neuropathic pain; however, it remains underdiagnosed, under-treated, and often requires long-term therapy with risk of adverse effects. Memantine (Namenda), an N-Methyl, D-aspartate receptor inhibitor currently marketed for the treatment of dementia, has been proposed as a medication for the treatment of neuropathic pain for its mechanism, safety, lack of serious adverse effects, and relatively rapid onset of action. However, clinical trials have not been promising so far and its routine use in neuropathic pain is not currently recommended.
神经病理性疼痛在姑息治疗人群中很常见；除非得到充分治疗，否则这种疼痛会导致慢性焦虑、抑郁和社会功能障碍。针对神经病理性疼痛已经提出了许多治疗方法；然而，它仍然诊断不足、治疗不足，并且常常需要长期治疗，存在不良反应风险。美金刚（易倍申）是一种目前用于治疗痴呆症的N-甲基-D-天冬氨酸受体抑制剂，因其作用机制、安全性、缺乏严重不良反应以及起效相对较快，已被提议作为治疗神经病理性疼痛的药物。然而，到目前为止临床试验效果并不理想，目前不建议在神经病理性疼痛中常规使用。
